Benefits to Attending

✓ Hear from and meet with the leading figures in the stem cell therapy field.

Attendees include: Vice President, GlaxoSmithKline; Director, CCRM;

Professor, University of Heildelberg

✓ Discover collaborative solutions to stem cell bioprocessing challenges.

This event brings together senior experts to address current trends in

bioprocessing strategies, development of stem cell technology platforms and

the genetic modification of stem cells

✓ Meet with key industry figures. Our industry spotlight presentations cover

advances in cell based therapies for regenerative medicine, manufacturing

challenges and how to streamline the delivery of stem cell therapies

✓ Discuss the latest innovations in stem cell therapy development: clinical

trials. Case studies include advances of innovative cell based therapies for

use in regenerative medicine, and organ regeneration and tissue engineering

case studies

✓ Unparalleled networking opportunities. The two-day congress offers

dedicated networking breaks creating an interactive platform for scientific

discussions and 1-1 meetings. The exhibition hall and poster presentation

spaces offer a relaxed and professional environment for discussion

✓ A high quality programme devised with the help of our esteemed

advisory board. Presentations to showcase updates in manufacturing

challenges, streamlining the delivery of stem cell therapies and updates in the

stem cell microenvironment

Meet Senior Decision Makers 250 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions w ill attend the event. Delegate job titles include:

Discover New Solutions Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Stem Cell Biology Cellular Therapeutics Cellular Reprogramming

Regenerative Medicine Process Development iPS Cells

Stem Cell Therapy Translational Medicine Stem Cell Manufacturing

Tissue Engineering Organ Regeneration Stem Cell Bioprocessing

Cell Activation & Expansion Stem Cell Production iPSC Manipultation

Tissue Printing Technologies Screening Tools Stem Cell Engineering

iPSC Reprogramming Cryopreservation Stem Cell Storage

Stem Cell Engineering Stem Cell Characterisation Stem Cell Differentiation

Day 1 – Stem Cell Bioprocessing • Development of stem cell technology platforms

and strategies, including: o Genetic modification of cells and stem cells for

clinical applications o Streamlining and standardizing the delivery of

genetically modified cells

• Recent advances in reprogramming & trans-differentiation techniques o In vivo vs ex vivo

• Derivation, manipulation, characterisation and bioprocessing of iPSCs

• Updates in tissue engineering

Day 2 Part 1 – Industry Spotlight Presentations • Advances of innovative cell based therapies for

use in regenerative medicine

• Stem cell manufacturing: meeting quality, quantity & safety requirements

• Streamlining the delivery of stem cell therapies – commercialisation vs the regulators

• Stem cell therapy in drug discovery and development

Part 2 - Stem Cell Therapy Development: Clinical Trials • Innovations in tissue engineering & organ

regeneration o Case studies from:

• Diabetes

• Stroke

• CNS

• 3D Biomaterial Culture Systems For Stem Cell Expansion

• Stem cell metabolism in tissue development and aging

• Updates of clinical trials for stem cell therapies o Allogenic stem cell modelling for human

disease o Stem cell banking and the benefits of cord

blood banking

For booking details & registration fees please refer to the last page or visit: www.celltherapy-congress.com/marketing

Do not miss out on our exclusive complimentary webinars: • CHO Host Cell Engineering and Expression Vector Development,

5th of September 2017 – Register for free.

• Regulatory Strategies To Implement Your Manufacturing

Processes, 12th of September 2017 - Register for free.

• 3D Biomaterial Culture Systems for Stem Cell Expansion, 13th of

September 2017 - Register for free.

2017 Speakers Include…

David Schaffer Susan Solomon Nagy Habib John Sinden Berkeley Stem Cell New York Stem Imperial College ReNeuron Center Cell Foundation London

Co-located with our prestigious 6th Annual Cell Culture

& Bioprocessing Congress and 3rd Annual Cell &

Gene Therapy Congress

For more information please contact marketing@oxfordglobal.co.uk

If you’re on Twitter, make sure to follow us @cellcultureconf and join the congress conversation on #STEM17 itter, make sure to follow us @cellcultureconf and join the congress conversation on #STEM17

____ and join the Congress conversation on #______

Confirmed Stem Cell Speakers:

• Sven Kili, Vice President and Head of Gene Therapy Development, GlaxoSmithKline

• Shailesh Gupta, Senior Scientist Bioscience, Stem & Primary Cell Group, AstraZeneca

• John Sinden, Chief Scientific Officer, ReNeuron

• Emily Titus, Director, Technology Development, Centre for Commercialization of Regenerative Medicine (CCRM)

• Susan Solomon, Chief Executive Officer and Co-Founder, New York Stem Cell Foundation

• Michaela Sharpe, Head of Non-Clinical Safety and Immunotherapy Strategy, Cell & Gene Therapy Catapult

• Janet Glassford, Senior Senior Quality Assessor, Biological/Biotechnology Unit, MHRA

• Nagy Habib, Professor, Imperial College of London

• Che Connon, Professor of Tissue Engineering, Newcastle University

• Anthony Ho, Professor & Chair, Department of Medicine, University of Heidelberg

• Timothy O’Brien, Director, Regenerative Medicine Institute, National University of Ireland Galway

• David Schaffer, Director, Berkeley Stem Cell Center, University of California, Berkeley

• Benedikt Berninger, Professor, University Medical Center, Johannes Gutenberg University Mainz

• Dominique Bonnet, Senior Group Leader, The Francis Crick Institute

• David Hay, Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh

• Baris Tursun, Principal Investigator, Max Delbruck Center for Molecular Medicine

• Paola Campagnolo, Group Leader in Molecular Cardiovascular Biology, University of Surrey

• Patrizia Camelliti, Team Leader; Cardiovascular Biology, University of Surrey and Honorary Research Fellow, Imperial College London

• Francesco Saverio Tedesco, NIHR Academic Clinical Fellow in Paediatrics, University College London Confirmed Cell & Gene Therapy Speakers:

• Rahul Aras, President, Co-founder & CEO, Juventas Therapeutics

• David Sourdive, Co-founder, Executive Vice President, Cellectis

• David Gilham, Vice President Research and Development, Celyad

• Stefanos Theoharis, Senior Vice President Corporate Development and Partnering, Cell Medica

• Alex Bloom, Vice President Global Regulatory Affairs, Cell Medica

• Sven Kili, Vice President and Head of Gene Therapy Development, GlaxoSmithKline

• Cedrik Britten, Vice President & Head of Oncology Cell Therapy DPU, GlaxoSmithKline

• Markwin Velders, Vice President, Operations, Kite Pharma

• Ajan Reginald, Chief Executive Officer, Celixir PLC

• Sylvain Arnould, Process Development & Production Director, Celyad

• Michael Mercaldi, Director, Purification Process Development and Manufacturing, Codiak Biosciences

• Joachim Scholpp, Global Head of Research Beyond Borders Clinical, Boehringer Ingelheim

• Katherine Tsokas, Regulatory Head of Regenerative Medicine & Advanced Therapy, Janssen Research & Development

• Tanvir Tabish, Head of Drug Product Development for Gene Therapy and Coagulation Factors, Shire

• Nitza Thomasson, Chief Preclinical Officer, Gensight Biologics

• Jacqueline Barry, Chief Clinical Officer, Cell Therapy Catapult

• Emily Culme-Seymour, External Strategy Manager, Gene Therapy, Rare Diseases Unit, R&D, GlaxoSmithKline

• Juliana Woda, Project Manager, BioMotiv

• Verena Vanessa Fischer, Lab Head in Early Stage Bioprocess Development, Boehringer Ingelheim

• Monicah Otieno, Director of Mechanistic & Investigative Toxicology, Janssen

• David Schaffer, Director, Berkeley Stem Cell Center, University of California, Berkeley

For more information please contact marketing@oxfordglobal.co.uk

2017 Cell Culture & Bioprocessing, Cell & Gene Therapy and Stem Cell Congress Sponsors Include: Lead Sponsor:

Congress Sponsors:

For more information please contact marketing@oxfordglobal.co.uk

4th Annual Stem Cell Congress Day One – 6th November 2017

07.30 – 08.20 Registration

08.20 – 08.25 Oxford Global’s Welcome Address

08.25 – 08.30 Chairperson’s Opening Address

08.30 – 09.00 Co-located Keynote Address: Regulatory Considerations For Expedited Quality Development And Bioprocessing • Pathways open for expedited development

• Expedited development approaches and regulatory strategies for dealing with these

• Review of a case study example

Diane Wilkinson, Director Global Regulatory Affairs CMC, Biogen

Stem Cell Bioprocessing

09.00 – 09.30 Precise Genome Modification Techniques To Introduce Gene Knock-Outs, Knock-In Mutations Or Endogenous Reporters Into iPS Cells • CRISPR/Cas9 in engineering iPS cells to generate cellular reagents for drug discovery

• Screening capabilities/methodologies for rare events

Shailesh Gupta, Senior Scientist Bioscience, Stem & Primary Cell Group, AstraZeneca

09.30 – 10.00 Solution Provider Presentation

10.00 – 11.20 Morning Coffee & Refreshments, One to One Meetings x3, Poster Presentation Sessions

11.20 – 11.50 The Generation And Characterization Of Patient-Specific iPSC Lines Emily Titus, Director, Technology Development, Centre for Commercialization of Regenerative Medicine (CCRM)

11.50 – 12.20 New Versatile Humanized Niche Model For Studying Human Normal And Malignant Hematopoiesis Dominique Bonnet, Senior Group Leader, The Francis Crick Institute

12.20 – 12.50

Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

12.50 – 13.50 Lunch

13.50 – 14.20 Realizing The Promise Of Stem Cell iPSC Research

Susan Solomon, Chief Executive Officer and Co-Founder, New York Stem Cell Foundation

14.20 – 14.50 Engineering The Limbal Stem Cell Niche • Mechanotransduction plays an important role in niche function

• A functional niche is more compliant than surrounding tissue

• Affecting tissue stiffness as a therapeutic modality in stem cell therapy

Che Connon, Professor of Tissue Engineering, Newcastle University

14.50 – 15.20

Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

15.20 – 16.20 Afternoon Coffee & Refreshments, One to One Meetings x2, Poster Presentation Sessions

16.20 – 16.50 Histone Chaperones Inhibit Cellular Reprogramming In The Nematode C. elegans And Human Cells • Specified cells have safeguarding mechanisms that restrict reprogramming

• Barrier factors that limit cellular reprogramming are evolutionary conserved

• Histone chaperone depletion enhances cellular reprogramming in C. elegans and human cells

Baris Tursun, Principal Investigator, Max Delbruck Center for Molecular Medicine

For more information please contact marketing@oxfordglobal.co.uk

4th Annual Stem Cell Congress Day One – 6th November 2017

Stem Cell Bioprocessing

16.50 – 17.20 Developing Predictive Human Liver Models From Pluripotent Stem Cells The development of renewable human liver models, from genetically defined origins, is likely to be a game-changing

addition to the field. However, for these models to have significant impact they must be stable in character and capable of manufacture at scale. For this reason, we have chosen to use pluripotent stem cells (PSCs). We have developed

highly efficient, scalable, and reliable differentiation procedures for use with PSCs, which demonstrate very promising qualities. In collaboration with industry and academic laboratories, we provide proof of concept that stem cell derived

hepatocytes can be produced by automation and applied to numerous biomedical questions. Our most recent advances

will be discussed at the meeting.

David Hay, Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh

17.20 – 17.50 Engineering of Neurogenesis via Lineage Reprogramming • Reprogramming of human pericytes into functional neurons by Ascl1 and Sox2

• Deconstructing the reprogramming process by single cell RNA sequencing

• Pericyte-to-neuron conversion involves the activation of a developmental neurogenic program

Benedikt Berninger, Professor, University Medical Center, Johannes Gutenberg University Mainz

17.50 – 18.20 Nanoneedles For Localised In Vivo Gene Therapy And Reprogramming • Nanomaterials deliver gene therapy in vivo to the heart

• Gene transfer and spatial cues promote cellular reprogramming

Paola Campagnolo, Group Leader in Molecular Cardiovascular Biology, University of Surrey

18.20 – 18.50 Stem Cell Bioprocessing And Tissue Engineering Francesco Saverio Tedesco, Principal Research Associate, Cell & Developmental Biology, Division of Biosciences, University College London

18.50 Networking Drinks & End of Day One

4th Annual Stem Cell Congress Day Two – 7th November 2017

Conference Room:

Stream Chair:

08.30 – 09.00 Keynote Address: Advances Of Innovative Cell Based Therapies For Use In Regenerative Medicine Sven Kili, Vice President and Head of Gene Therapy Development, GlaxoSmithKline

Part 1 – Industry Spotlight Presentations 09.00 – 09.30 The Development Of Novel Stem Cell Therapeutics For Stroke Disability

John Sinden, Chief Scientific Officer, ReNeuron

09.30 – 10.00 Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

10.00 – 11.00 Morning Coffee & Refreshments, One to One Meetings x2, Poster Presentation Sessions

11.00 – 11.30 Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

11.30 – 12.00 The Role Of Governments In The Commercial Emergence Of Radical Innovation – The Field Of Regenerative Medicine • Barriers to innovation

• Investing in science, research and innovation

• Strengthening strategic capability

Michaela Sharpe, Head of Non-Clinical Safety and Immunotherapy Strategy, Cell & Gene Therapy Catapult

For more information please contact marketing@oxfordglobal.co.uk

4th Annual Stem Cell Congress Day Two – 7th November 2017

Part 1 – Industry Spotlight Presentations 12.00 – 12.30 Stem Cell Application In Regenerative Medicine And Drug Discovery – With A Particular Focus On The

CNS System Reserved for: Robert (Willie) Mays, Vice President of Regenerative Medicine and Head of Neuroscience Programs, Athersys

12.30 – 13.00 Panel Discussion: Stem Cell Manufacturing: Meeting Quality, Quantity & Safety Requirements Invitation to: Robert (Willie) Mays, Vice President of Regenerative Medicine and Head of Neuroscience Programs, Athersys John Sinden, Chief Scientific Officer, ReNeuron David Gilham, Vice President Research and Development, Celyad Shailesh Gupta, Senior Scientist Bioscience, Stem & Primary Cell Group, AstraZeneca

13.00 – 14.00 Lunch

Part 2 - Stem Cell Therapy Development: Clinical Trials 14.00 – 14.30 Quality Of ATMPs – A European Regulator’s Perspective

• Negotiating the regulatory maze

• Our approach to assessment of Quality data

• Common themes

Janet Glassford, Senior Senior Quality Assessor, Biological/Biotechnology Unit, MHRA

14.30 – 15.00 Engineering Defined, Scalable, 3D Biomaterial Culture Systems For Stem Cell Expansion And Differentiation • Stem cells are highly promising for a range of clinical applications, but it is challenging to produce cells at the large

scales needed

• 3D culture will arguably be required to harness the potential of stem cells for many therapeutic applications, particularly

ones involving large patient populations and/or cell dosages

• A defined biomaterials system that offers precise control over stem cell self-renewal and differentiation in 3D holds

considerable promise as a 3D, scalable stem cell culture platform

David Schaffer, Director, Berkeley Stem Cell Center, University of California, Berkeley

15.00 – 15.30 The Non-IPSC Approach For Diabetes Nagy Habib, Professor, Imperial College of London

15.30 – 16.00 Afternoon Coffee & Refreshments, One to One Meetings x2, Poster Presentation Sessions

16.00 – 16.30 Translating Stem Cell Therapies To The Clinic In The EU • MSCs can be used to treat diabetic complications

• Early stage clinical trials are underway or are approved by our group in critical limb ischemia, non-healing diabetic foot

ulcers and diabetic nephropathy

• The regulatory experience will be described and an update on clinical trial progress presented

Timothy O’Brien, Director, Regenerative Medicine Institute, National University of Ireland Galway

16.30 – 17.00 Molecular Hallmarks Of Functional Decline In Human Haematopoietic Stem Cells (HSC) Upon Ageing • Comprehensive, comparative proteomics performed in human HSCs as well as in cells of the marrow niche (n=59

human subjects; age range 20 to 60 years) showed significant alterations in glycolytic metabolism reminiscent of Warburg effect

• Age-dependent decline in bone marrow function is associated with an increase in granulocytic inf lammatory processes

at the expense of lymphoid development

Anthony Ho, Professor & Chair, Department of Medicine, University of Heidelberg

17.00 – 17.30

Engineering Mature Cardiac Tissue For Drug Discovery And Development • Engineered heart tissue representative of adult myocardium is needed for drug screening and early identification of the

cardiac side effect of many drugs

• Human induced pluripotent stem cell-derived cardiomyocytes cultured under controlled conditions able to mimic the

native cardiac environment could provide a suitable model

• Human ultrathin heart slices provide benchmark human heart data essential for the validation and optimisation of the

engineered heart tissue

Patrizia Camelliti, Team Leader; Cardiovascular Biology, University of Surrey and Honorary Research Fellow, Imperial College London

17.30 End of Conference

4th Annual Stem Cell Congress 3rd Annual Cell & Gene Therapy Congress

Conference: 6 - 7 November 2017, 99 City Road Conference Centre, London, UK www.stemcells-congress.com & www.celltherapy-congress.com

HOW TO REGISTER: FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

Please complete fully and clearly. Please photocopy for additional delegates Title:_____Forename:_______________Surname:________________ Job Title:_________________________________________________ Company/Organisation:_____________________________________ Email:___________________________________________________ Address:_________________________________________________ ________________________________________________________ Postcode: ____________________ Country: ___________________ Direct Telephone ________________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: _____________________

Number of delegates:

Industry del(s) Academic dels(s) Vendor dels(s) Special Offer: 3 for 2

Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:

Valid from: / Expiry Date: /

Security code:

Cardholders name: _______________________________________

Signature: ______________________________ Date: ___________

PLEASE INVOICE ME:

Invoice Address (if different from above)_______________________

*Please note there is a £50 plus VAT handling charge for payment via invoice *All card payments will be subject to a 3% bank charge or 4% AMEX charge

Registration Fees

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded. I agree to the above Terms and Conditions

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies)

Congress £799 plus VAT 1 day pass £499 plus VAT Day 1 Day 2

Academic Delegates Congress £499 plus VAT 1 day pass £299 plus VAT Day 1 Day 2

Vendor Delegates (CROs, Consultants, Technology and Service Providers) Congress Only £1350 plus VAT

1 day pass £799 plus VAT Day 1

Day 2 Poster Presentation £250 plus VAT PROMOTIONAL LITERATURE DISTRIBUTION

Distribution of your company’s promotional literature to all conference attendees £999 plus VAT

Documentation

I cannot attend but would like to purchase access to the following: Access to the online conference presentations £499 plus VAT Conference presentations - paper copy £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk

Terms & Conditions of Booking

Delegate Details